Abstract
Swab, quantitative, reverse transcription polymerase chain reaction (RT-qPCR) tests remain the gold standard of diagnostics of SARS-CoV-2 infections. However, these tests are costly and time-consuming, and swabbing limits their throughput. We developed a 3-gene, seminested RT-qPCR test with SYBR green-based detection, optimized for testing pooled saliva samples for high-throughput diagnostics of epidemic-affected populations. The proposed two-tier approach depends on decentralized self-collection of saliva samples, pooling, 1st-tier testing with the mentioned highly sensitive screening test and subsequent 2nd-tier testing of individual samples from positive pools with the in vitro diagnostic (IVD) test. The screening test was able to detect 5 copies of the viral genome in 10 µl of isolated RNA with 50% probability and 18.8 copies with 95% probability and reached Ct values that were highly linearly RNA concentration-dependent. In the side-by-side comparison (testing artificial pooled samples), the screening test attained slightly better results than the commercially available IVD-certified RT-qPCR diagnostic test (100% specificity and 89.8% sensitivity vs. 100% and 73.5%, respectively). Testing of 1475 individual clinical samples pooled in 374 pools of 4 revealed 0.8% false positive pools and no false negative pools. In weekly prophylactic testing of 113 people within 6 months, a two-tier testing approach enabled the detection of 18 infected individuals, including several asymptomatic individuals, with a fraction of the costs of individual RT-PCR testing.
Competing Interest Statement
Jarosław Dastych is the CEO of Proteon Pharmaceuticals S.A., which offers the presented method as a commercial service.
Funding Statement
This work was funded by Proteon Pharmaceuticals S.A. and statutory funds of the Institute of Medical Biology of PAS
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The usage of anonymized samples from patients of the Center of Molecular Diagnostics of Pathogens, Proteon Pharmaceuticals S.A. in the study was approved by the Bioethical Committee at the University of Lodz (Res. nr 3/KBBN-UŁ/I/2020-21).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Funding: This work was funded by Proteon Pharmaceuticals S.A. and statutory funds of the Institute of Medical Biology of PAS
Conflict of interest: Jarosław Dastych is the CEO of Proteon Pharmaceuticals S.A., which offers the presented method as a commercial service.
Abbreviations
- RT
- reverse transcriptase
- RT-qPCR
- quantitative reverse transcription polymerase chain reaction
- IVD
- in vitro diagnostics (certificate)
- dNTP
- deoxyribonucleotide triphosphate
- DEPC
- diethyl pyrocarbonate
- GAPDH
- glyceraldehyde 3-phosphate dehydrogenase
- Tm
- melting temperature
- Ct
- threshold cycle (in quantitative PCR)
- CI
- confidence interval
- HBSS
- Hanks’ balanced salt solution
- PPE
- personal protective equipment
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.